Clinical trial NCT04586621: Evaluation of the Performance and Safety of the Atoldys/ Lexilens Glasses Developed to Improve the Reading of Dyslexic Subjects
Official title: Evaluation of the Performance and Safety of the Atoldys/ Lexilens Glasses Developed to Improve the Reading of Dyslexic Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dyslexia
Lead sponsor: ABEYE
Sponsor class: INDUSTRY
Collaborators: name: Slb Pharma
First posted: 2020-10-14
Enrollment: 41
Sex: ALL
Minimum age (years): 8
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the efficacy and safety of a new medical device (Atoldys/ Lexilens glasses) on the improvement of reading skills of young dyslexic subjects.

Detailed description: Dyslexia is defined as a specific learning disability that is characterized by reading difficulties, in the absence of intellectual disability, neurological or psychiatric disorder, uncorrected sensory disturbance (sight, hearing) or an educational deficiency.

Dyslexia appears in the child from the earliest stages of learning in the form of a difficulty in mastering the learning of reading. This disorder is manifested by a generally hesitant reading, slowed down, full of errors, requiring a lot of effort for the child and may impact his reading comprehension. The dyslexia-related deficiency is of variable intensity depending on the individual; it may be accompanied by calculus disorders (dyscalculia), oral language (dysphasia), motor coordination (dyspraxia) or attention disorders with or without hyperactivity. In nearly 40% of cases, a child affected by Dys disorders presents several learning disorders.

To date, the causes of dyslexia are not yet clearly established. The wide variety of symptoms and disorders associated with dyslexia does not facilitate the identification of precise neurobiological / psycho cognitive mechanisms. There are therefore several theories: phonological, visual, temporal, cerebellar or proprioceptive auditory processing.

Recently, following work published in 2017, an anatomical cause based on Maxwell's spots could also be a cause of dyslexia.

The aim of this study is to evaluate a new medical device (class I CE marked) to compensate this probable anatomical cause: the Atoldys/ Lexilens glasses

Eligibility criteria: Inclusion Criteria:

* Schooled in CM1, CM2 or 6ème,
* French mother tongue,
* For whom developmental dyslexia has been diagnosed by a health professional who specializes in this learning disorder,
* With near vision, without optical correction, equivalent to P5 or better according to the Parinaud scale (distance: 30-40 cm),
* Presenting an IQ ≥ 80 and ≤130 according to the WISC-V test performed by a psychologist,
* For whom a written consent was obtained regarding his study participation.

Exclusion Criteria:

* With medical history or presenting a neurological pathology,
* Presenting a developmental disorder (autism, ADHD, ...),
* Presenting hearing disorders,
* Presenting an astigmatism of more than one uncorrected diopter,
* Presenting other visual disorders,
* Any other condition that, in the opinion of health professionals, could impair its ability to complete the study or could pose a significant risk.

Primary outcomes:
measure: Reading performance aloud of a text with french E.L.FE Test
timeFrame: 1 day
Secondary outcomes:
measure: Reading performance aloud of isolated words with french BALE Test
timeFrame: 1 day
measure: Security: incidence of Adverse Events
timeFrame: 1 day
measure: Security: device deficiencies
timeFrame: 1 day
measure: Child's satisfaction regarding reading fluency and comprehension
timeFrame: 1 day
measure: Speech therapist's satisfaction regarding Securirty, Performance and Usability of glasses
timeFrame: 1 day
Other outcomes:
Locations:
city: Caen
country: France
facility: Dr Laurence Derieux
city: Faumont
country: France
facility: Dr Luc-Marie Virlet
city: Rennes
country: France
facility: CHU Rennes
Study officials:
References: